Corbus Pharmaceuticals Holdings, Inc. (CRBP)
- Previous Close
37.74 - Open
37.97 - Bid 30.33 x 100
- Ask 35.84 x 100
- Day's Range
34.24 - 38.34 - 52 Week Range
3.03 - 49.87 - Volume
219,990 - Avg. Volume
992,596 - Market Cap (intraday)
373.426M - Beta (5Y Monthly) 2.47
- PE Ratio (TTM)
-- - EPS (TTM)
-10.31 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
55.00
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
www.corbuspharma.comRecent News: CRBP
Performance Overview: CRBP
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRBP
Valuation Measures
Market Cap
373.43M
Enterprise Value
373.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.49k
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-8.40
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.57%
Return on Equity (ttm)
-341.98%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-44.6M
Diluted EPS (ttm)
-10.31
Balance Sheet and Cash Flow
Total Cash (mrq)
20.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-21.24M